Otonomy Announces Publication of OTIPRIO™ Phase 3 Clinical Trial Results in JAMA Otolaryngology

Back to Jobs

SAN DIEGO , March 18, 2016 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the publication of the positive results of the Phase 3 clinical

Apply Now